Populaiton Pharmacodynamics of Vamicamide, a New Anticholinergic Drug, Analyzed by Nonlinear Mixed Effect Modeling. Relationship between the Average Urine Flow Rate and Serum Concentration in Healthy Volunteers.:Relationship between the Average Urine Flow
スポンサーリンク
概要
- 論文の詳細を見る
The population pharmacodynamics of vamicamide, a new anticholinergic drug, were analyzed by nonlinear mixed effect modeling (NONMEM) in 16 healthy male subjects. The subjects were given orally 18, 36 or 48 mg of vamicamide in a single- or multiple-dose regimen. Serum concentrations of vamicamide were measured frequently; the average urine flow rates (AFRs), estimated simply by dividing the urine volume by the time during voiding, were measured on each occasion of urination. Serum concentrations corresponding to the time of urination were predicted by curve-fitting the individual data (a total of 293 serum data) to a one-compartment model with first-order absorption. The serum concentration-AFR data (381 data pairs) thus obtained were used for NONMEM analysis. The Emax model with baseline controls was used for serum concentration-AFR response data. The voided volume significantly affected not only the baseline AFR but also maximum response (Emax). However, the concentration which causes half of Emax (EC<SUB>50</SUB>) was independent of voided volume and was estimated to be 167 ng/ml. At the serum concentration of 140 ng/ml, which is the maximum serum concentration at therapeutic standard dosage regimen, the percent reduction of AFR from the baseline value was estimated to be 32 and 38% when the voided volume is assumed to be 100 and 400 ml, respectively. Despite the wide range of variability in AFR, the NONMEM analysis provided clinically significant concentration-response curves. This population approach appears recommendable for further clinical applications.
- 一般社団法人 日本臨床薬理学会の論文
著者
関連論文
- 喫煙が好中球エラスターゼ阻害吸入剤の体内薬物動態に及ぼす影響
- N-アセチル転移酵素およびCYP2C19多型の遺伝子診断と薬物動態・治療効果との相関解析
- Microsoft Excel^【○!R】で利用可能なモーメント解析プログラムMOMENT (EXCEL)
- マイクロソフト Excel におけるモーメント自動計算プログラムの開発
- 22C-21 災害時の処方内容と薬剤部の対応
- In vitroにおけるmicafunginの薬物相互作用
- マウス, ラットおよびイヌにおけるmicafungin単回静脈内投与後の体内動態, in vitro血清蛋白結合および血球移行性
- Testosterone 5α-reductase阻害剤(FK143)のラット前立腺におけるpharmacokinetics/pharmacodynamics
- 25-04-18 抗不整脈剤シベンゾリンの TDM 解析支援ソフトのベイジアン法による体内動態パラメータ推定精度評価
- 非血液検体を用いたCYP2C19多型の遺伝子タイピング
- ヒト二相性イソフェンインスリン水性懸濁製剤の含量均一性についてのバリデーション
- 38 ジヒドロピリジン系カルシウム拮抗剤ニルバジピンのヒトにおける立体選択的薬物動態
- ラットにおける^C標識micafungin単回静脈内投与後の分布および排泄
- ヒト血漿中micafunginおよびその代謝物濃度の高速液体クロマトグラフィーによる定量法
- 薬物体内動態修飾因子の検討 : 高齢被験者を対象として
- 新規アンジオテンシンII受容体拮抗薬カンデサルタン・シレキセチル(TCV-116)のPopulation Pharmacokinetics
- Levofloxacin 組織移行動態の解析と感染部位ごとの至適投与量の設定
- 薬物代謝能の遺伝子タイピングとTDM
- N-アセチルトランスフェラーゼ遺伝子多型性と体内動態パラメータとの相関
- 新規インスリンカートリッジ製剤の含量均一性についてのバリデーション
- ラットおよびイヌにおけるmicafunginの代謝物
- Clinicopharmacological research of FK505 in normal subjects.
- Clinicopharmacological research of FK453 in normal subjects.
- Clinical-pharmacological research of dopexamine in normal subject.
- Examination of drug disposition kinetic modifying factor. Subject to old examinees.
- Correlation between N - acetyltransferase gene polymorphism and pharmacokinetics parameter.
- タイトル無し
- Populaiton Pharmacodynamics of Vamicamide, a New Anticholinergic Drug, Analyzed by Nonlinear Mixed Effect Modeling. Relationship between the Average Urine Flow Rate and Serum Concentration in Healthy Volunteers.:Relationship between the Average Urine Flow